BUSINESS
Despite strong run, pharma and healthcare stocks still have some steam left, says Chirag Dagli of DSP MF
According to Dagli, the strong growth trajectory expected of the sector also supports its valuation metrics. He also expects the various segments within the pharma and healthcare space to perform well in the near term.
BUSINESS
Will the dollar index usher in a bull run in Indian markets?
There is anticipation that the dollar index will stay within the 100-mark, bringing FII inflows into India and propping up the markets.
BUSINESS
Is 2023 going to be the stellar season for IPOs?
A vibrant secondary market often enhances the allure of the primary market, as more investors are likely to bid for new issues when the overall sentiment is upbeat. Analysts cited this factor as a major trigger for the rise in the number of IPOs hitting the Street since March.
BUSINESS
With roadblocks out of the way, is Lupin finally on the growth path?
The growing positivity around Lupin is clearly demonstrated in the stock’s performance, which has spiked over 38 percent since the start of April. However, some analysts believe the valuation is a bit stretched.
BUSINESS
A healthy love affair continues as healthcare stocks remain MF darlings
Ten out of 11 mutual fund houses covered by Nuvama Alternative & Quantitative Research have gone overweight on pharma and healthcare, as against their weightage in Nifty 200.
BUSINESS
Paint makers in blues as surge in crude oil may jack up input costs
Even though most brokerages had predicted some margin recovery for paint companies in Q1, the trends of rising input costs and increasing competition may soon water down those expectations.
BUSINESS
Indian pharma market records a blip, but stays the course for fresh rally
A delayed monsoon and reduced demand for acute products impacted the industry briefly, but analysts expect the sector to sustain double-digit growth figures for the year.
BUSINESS
Healthcare sector on robust growth path; here's why
Demand for wellness, better health awareness and greater access to medical facilities will drive the growth of all players in the healthcare industry and associated sectors.
BUSINESS
Pipeline Check: Here are the blockbuster drugs lined up by Indian drugmakers for US launch
Cipla is rolling out plans to launch a generic of Advair while Lupin has got approval for Spiriva
BUSINESS
Why is Indian pharma failing to meet US standards?
BUSINESS
F&O Manual: New day, new high for Nifty, but traders sound caution as day progresses
BUSINESS
Can Nifty sustain its mojo in July F&O series? Here's what rollovers say
BUSINESS
Jefferies positive on Mankind Pharma's growth prospects but valuations remain a sore point
BUSINESS
Can Indian chemicals companies stand strong against global demand concerns?
BUSINESS
What's on offer: What does buying stake in Mylab mean for Zydus?
BUSINESS
The big picture: Are Ipca's regulatory woes actually a negative?
BUSINESS
Mid-sized hospitals can deliver outsized returns
BUSINESS
Lupin's much-awaited approval for gSpiriva is here; will it change the drug maker’s fortunes?
BUSINESS
Who's winning the game in the Indian pharma market?
BUSINESS
Is the pharma sector on the road to regaining its mojo?
BUSINESS
HDFC Sec sees 10% upside potential in Rainbow Children's Medicare, here's why the optimism
BUSINESS
Indian Pharma Market records strong growth for second straight month in May
BUSINESS
Several large block deals in Axis Bank; Bain Capital likely seller
BUSINESS
Mankind, P&G and Alkem shine as healthcare stocks grab biggest pie of MF investments in May
